The Health Insurer Nobody Took Seriously Just Delivered a Breakout Quarter
Membership up 56%. MLR down 5%. Free cash flow of $2.6 billion in a single quarter. Best quarter in history, by a significant margin. The market is starting to notice.
Oscar Health OSCR 0.00%↑ has spent most of its public life being dismissed.
Too small. Too tech-forward for a business where margins are measured in basis points. Too dependent on a regulatory environment that could shift under its feet.
The ACA exchange market is volatile, the argument went, and Oscar was too concentrated in it to build a durable business.
Q1 2026 kind of proved those critics wrong.
Oscar is not a speculative bet on an ACA enrollment story anymore. It is a rapidly scaling health insurance business with a technology platform, a proven MLR improvement trajectory, and an increasingly clear path to sustained profitability. The valuation still carries a premium and the regulatory backdrop is a genuine variable. But the business underneath the uncertainty is materially stronger than it was twelve months ago.
The stock is up over 60% from its February lows. The question for investors now is whether this is a momentum trade that has already run, or the early stages of a re-rating toward what this business is actually worth at scale.
Key Takeaways
Q1 2026 total revenue of $4.65B, up 53% year over year, driven by membership growth and disciplined rate increases
Medical loss ratio of 70.5%, down from 75.4% in Q1 2025, a 5% structural improvement
Total membership of 3.17M, up 56% year over year from 2.04M in Q1 2025
Net income of $679M, or $2.07 diluted EPS, versus $275M and $0.92 in Q1 2025
Adjusted EBITDA of $727M in Q1 2026, up from $329M in Q1 2025
Q1 2026 free cash flow of $2.61B; TTM free cash flow of $2.80B
Cash and equivalents of $4.81B as of March 31, 2026; total debt just $431M
What Oscar Does, and Why It Matters More Now
Oscar is a health insurance company built around the individual and family plan market under the Affordable Care Act. It sells directly to consumers, competes on plan design, pricing, and digital experience, and collects premiums while managing the medical cost ratio that determines whether those premiums generate a profit.
What differentiates Oscar from legacy managed care operators is the technology layer. Oscar built its own full-stack platform covering member onboarding, care navigation, utilization management, and claims processing. That platform is not just an operational efficiency tool. It is the basis for Oscar’s +Oscar business, which licenses the technology to other health plans and providers, and for Lucie Health Marketplace, which extends Oscar’s consumer distribution capability beyond its own insurance book.
Three structural forces are working in Oscar’s favor right now. First, the individual market has proven larger and more resilient than most expected. Oscar has demonstrated it can grow its member base aggressively while simultaneously improving unit economics. Second, the workforce is continuing to shift away from employer-sponsored coverage toward gig, freelance, and contract arrangements, expanding the addressable pool year after year. Third, consumers increasingly behave like shoppers when choosing health coverage, comparing plans on price and value rather than defaulting to an employer’s offering. Oscar’s digital-native model was built for exactly that dynamic.
The Q1 2026 results confirm that the combination of membership scale and pricing discipline is producing the operating leverage the bull case always assumed would eventually arrive. It has arrived.
Fundamental Analysis
Revenue and Earnings
Oscar’s revenue growth over the past four years tells the story of a business that kept scaling through profitability struggles and came out the other side with real momentum.
FY2022: $4.13B
FY2023: $5.86B (+42%)
FY2024: $9.18B (+57%)
FY2025: $11.70B (+27%)
TTM: $13.30B
Q1 2026 alone: $4.65B (+53% vs. Q1 2025)
That is a business that has more than tripled revenue in three years. The acceleration in Q1 2026 on top of an already large base is what makes this quarter notable.
Profitability history:
FY2022: Net loss of $606M
FY2023: Net loss of $271M
FY2024: Net income of $25M (first profitable full year)
FY2025: Net loss of $443M (driven by unusual items and adverse development)
Q1 2026: Net income of $679M
The FY2025 loss looks jarring against the Q1 2026 result, but it reflects the timing of adverse reserve development and unusual items rather than a reversal of the underlying improvement trajectory. The Q1 2026 number is the cleaner signal of where the operating business actually stands.
Margins and Profitability
The medical loss ratio is the single most important metric for an insurance business. It measures medical claims as a percentage of net premiums. Lower is better.
MLR progression:
Q1 2025: 75.4%
Q1 2026: 70.5% (-490bps year over year)
The improvement reflects disciplined 2026 plan year pricing, favorable claims seasonality from metal and new member mix, and $68 million of favorable prior period reserve development. For context, the same line showed $31 million of unfavorable development in Q1 2025, so the swing was roughly $99 million, meaningful but not the entire story. The underlying pricing discipline is real.
The SG&A expense ratio declining from 15.8% to 15.2% confirms fixed cost leverage is building. Each incremental member adds premium revenue with a disproportionately smaller increase in administrative overhead. This is the operating model working as intended.
Cash Flow and Capital Returns
FY2022: $351M
FY2023: -$298M
FY2024: $950M
FY2025: $1.06B
Q1 2026: $2.61B (single quarter)
TTM: $2.80B
The Q1 2026 free cash flow of $2.61 billion in a single quarter is the headline number. It reflects strong operating performance alongside the working capital dynamics of a growing insurance business, primarily the buildup of risk adjustment payables to CMS which grew from $2.73B to $4.72B during the quarter. This is a mechanical feature of the ACA risk adjustment program, not a cash flow concern in the traditional sense.
Operating cash flow for FY2025 was $1.09B, up from $978M in FY2024, continuing a multi-year improvement from the -$272M in FY2023.
Oscar does not pay a dividend and has not conducted share repurchases. Capital is being retained to fund growth and strengthen the balance sheet.
Balance Sheet
As at March 31, 2026:
Cash and equivalents: $4.81B (up from $2.77B at year-end 2025)
Total investments: $3.26B
Total assets: $9.29B
Total debt: $431M
Common equity: $1.66B (up from $978M at year-end 2025)
The balance sheet is in the strongest shape in Oscar’s public history. Debt-to-total capital sits at approximately 20%, and with $4.81B in cash against $431M in debt, Oscar is effectively net cash positive by over $4 billion. Equity has nearly doubled in a single quarter due to the profitability of Q1 2026.
The accumulated deficit of $2.62B is the legacy of the years spent building the platform and scaling membership. It is now shrinking at a meaningful pace.
Guidance
Management reaffirmed full year 2026 guidance across all metrics including total revenue, MLR, SG&A expense ratio, and earnings from operations. No numbers were revised from the February 10, 2026 guidance issuance. Holding guidance after a very strong Q1 is notable because insurance businesses are seasonal and Q1 is typically the strongest quarter for MLR due to deductible resets. The reaffirmation implies management sees the full-year trajectory, including expected seasonal MLR deterioration in later quarters, as tracking within the original plan.
Valuation
Current price: ~$21
Market cap: ~$6.4B
Enterprise value: ~$2.09B (reflecting the large net cash position)
TTM P/E: Negative (TTM net income still slightly negative due to FY2025 drag)
Forward P/E: ~23x
Price / LTM sales: ~0.48x
EV / EBITDA: ~52x trailing; annualizing Q1 2026 EBITDA implies closer to 10-12x on a run-rate basis
Price / book: ~3.85x
The valuation picture requires context. At 0.48x revenue for a business growing at 50%+ with rapidly improving margins, the revenue multiple is not demanding by any growth-adjusted standard. The EV/EBITDA of 52x on a trailing basis looks stretched, but it compresses rapidly when you annualize the Q1 2026 run rate. The forward P/E of 23x is the most relevant anchor for swing traders and medium-term investors.
Peers for context: Centene trades at a forward P/E of ~16x, Molina at ~39x, UnitedHealth at ~20x. Oscar’s 23x forward multiple sits in a reasonable range given the growth differential.
Technical Analysis
The Big Picture: Weekly Chart
The weekly chart tells a complete story of a stock that bottomed, rebuilt, and launched with conviction. OSCR 0.00%↑ declined from its 2024 highs through a multi-quarter corrective structure that carried price all the way down to approximately $11 in early 2026. From that low, the recovery has been sharp and impulsive.
Price has now reclaimed all four key EMAs on the weekly chart. The 20 EMA at $15.55 and the 50 EMA at $15.58 have both turned upward. Weekly RSI is at 66.63, constructive but not overbought at this timeframe, with meaningful room to run. The weekly MACD is in the early stages of a bullish crossover with the histogram turning positive.
This is the profile of a new uptrend beginning, not a dead-cat bounce. The key structural question the weekly chart poses is whether the current advance is the start of a fresh impulsive leg or a corrective bounce within a larger incomplete structure. The weight of evidence currently favors the former, but this gets resolved definitively only with sustained closes above the $22-24 zone.
Daily Chart
The daily picture is more extended but remains bullish. Price cleared the 200 EMA decisively on the Q1 earnings catalyst on May 6, gapping from the $15-16 range up through $18-19 on enormous volume, and has continued pushing higher in the sessions since. The 20 EMA on the daily is now at $17.65 and rising steeply, well below current price, reflecting the ferocity of the post-earnings move.
The daily RSI reached 82.71 with the signal line at 76.04. This is overbought territory by any conventional measure and is a clear caution flag for anyone considering immediate entry. The MACD on the daily is deeply positive, confirming the trend is intact but equally confirming momentum is stretched short-term.
A healthy pattern from here would involve consolidation or a modest pullback toward the $18.50-19.50 zone, allowing momentum to reset before any continuation.
Momentum Across Timeframes
Weekly: RSI 66.63, MACD early bullish crossover, EMA stack aligned bullish. Constructive, room to run.
Daily: RSI 82.71, MACD deeply positive, price well above all EMAs. Extended, caution on new entries.
2-hour: RSI 81.40, MACD positive with histogram fading slightly. Overbought short-term.
1-hour: RSI 74.08, MACD positive with signal line close. Elevated, watch for pullback trigger.
30-min: RSI 67.47, slight negative histogram developing. Cooling from hot, early normalization.
5-min: RSI 69.92, flat to slightly negative histogram. Near-term consolidation pattern.
The dominant read across timeframes: strong trend, short-term extended. The weekly structure is genuinely bullish and not overbought at that level, which is the more important signal for swing investors. The daily and intraday readings warn against chasing current price. The optimal entry window for this leg has passed. The next one requires patience.
Key Levels
Support:
$19.80-20.20: Post-earnings consolidation base; first pullback zone
$18.50-19.00: Daily 20 EMA converging with prior breakout area; primary dip-buy zone
$17.50-17.80: Intermediate support shelf and partial gap fill from earnings day
$15.50-16.00: Pre-earnings consolidation base; structural stop territory
Resistance:
$21.50-22.00: Immediate resistance; current test zone
$23.00-23.50: Prior supply cluster and wave projection zone
$24.50-25.00: Fair value estimate region and 2024-2025 prior highs
$27.00+: Stretch target if new institutional accumulation accelerates
Trade Plan
Position bias: Long, trend-following. Do not chase at current levels. Wait for the setup to come to you.
Time horizon: 1-3 months (swing), with Q2 earnings as the next major catalyst to frame around.
Entry zones:
Primary entry: $18.50-19.50
The ideal pullback zone where the daily 20 EMA, prior breakout area, and first meaningful demand shelf converge. The trigger is stabilization and a reclaim of $19.50 on a closing basis after a dip into this zone. This is the highest-quality entry available if the trend remains intact.
Secondary entry: $17.50-18.00
Deeper pullback zone and partial gap fill. If price reaches this area and shows clear buying absorption, it offers better risk-reward with a tighter invalidation point. Confirmation preferred over anticipation.
Breakout entry: Above $22.00 on a daily close with meaningful volume.
If price consolidates in the $20.50-21.50 range for several sessions and then breaks cleanly higher, that continuation is tradeable with a stop just below the consolidation base.
Stops / invalidation:
Tactical stop: Below $17.00
A clean break under this level after entering in the primary zone damages the near-term structure. Reduce or exit and reassess.
Structural stop: Below $15.00
Below the pre-earnings base and structural demand shelf. This level being lost means the post-earnings thesis is broken. Step aside entirely.
Targets:
T1: $23.00-23.50 First extension zone. Book partial profits; allow the remainder to run if momentum holds.
T2: $24.50-25.00 Fair value estimate zone and prior structural highs. At this level, consider full or near-full exit and wait for the next base to form.
T3 (stretch): $27.00+ Only viable in a strong momentum environment with volume confirmation and a clean hold above $25. Do not plan around this; let it come if it comes.
The Bottom Line
OSCR 0.00%↑ is no longer a bet on a concept. It is a business that has more than tripled revenue in three years, crossed into genuine profitability, and generated $2.6 billion in free cash flow in a single quarter. The market is beginning to price that in.
The bull case: 53% revenue growth. 490bps MLR improvement. $679M net income in a single quarter. Membership at 3.17M and still growing. $4.8B in cash against $431M in debt. Fixed cost leverage accelerating. A technology platform with real optionality beyond the insurance book. Fair value of $24.78 implies meaningful upside from current price.
The bear case: The Q1 MLR of 70.5% is seasonally favorable and unlikely to hold through the year. Risk adjustment liabilities are large and growing. ACA policy uncertainty is a permanent overhang. The stock has already moved 60%+ from its lows and short-term overbought conditions are real. The FY2025 loss is a reminder that this business can still surprise to the downside when development goes against it.
The trade here is not to chase. It is to let the momentum cool, wait for the structure to offer a cleaner entry in the $18.50-19.50 zone, and position with defined risk against a thesis that is now backed by one of the strongest quarters this company has ever reported.
OSCR 0.00%↑ does not need to be perfect to work from here. It just needs to keep delivering.
This content is for informational and educational purposes only and reflects our views at the time of writing. It is not investment advice or a recommendation to buy or sell any security. Markets involve risk, prices can move against you, and outcomes are never guaranteed. Always do your own research and consider your risk tolerance before making investment decisions.